Search results
Results from the WOW.Com Content Network
On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for sustained long-term growth and innovations in structural heart therapies.
Edwards on Thursday forecast 2024 TAVR sales in the range of $4.0 billion to $4.3 billion, compared with analysts' estimate of $4.23 billion. Edwards Lifesciences to spin off critical care unit to ...
(Reuters) -Edwards Lifesciences Corp on Wednesday reported a rise in third-quarter sales, but lower-than-expected sales of the company's artificial heart valves pushed the device maker's shares ...
Edwards lifted its 2023 sales forecast to between $5.9 billion and $6.1 billion, from $5.6 billion to $6.0 billion estimated earlier. The new mid-point is slightly higher than analysts' estimates ...
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter . [ 4 ]
Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
For premium support please call: 800-290-4726 more ways to reach us